High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

Kastrup, Jens; Johansen, Julia S.; Winkel, Per; Hansen, Jørgen Fischer; Hildebrandt, Per; Jensen, Gorm; Jespersen, Christian M.; Kjøller, Erik; Kolmos, Hans Jørn; Lind, Inga; Nielsen, Henrik; Gluud, Christian

doi:10.1093/eurheartj/ehp049

Cited by 156 publications

(147 citation statements)

References 31 publications

Supporting

Mentioning

129

Contrasting

Order By: Relevance

“…A significant correlation between YKL-40 plasma levels and age has been a matter of agreement (19,20,22,23,25,26,(28)(29)(30) or disagreement (14, 31-34) (like ours) in different studies. Such pros (23,24,35) (like ours) and cons (13,14,19,27) issues are also true in the case of the significant correlation between YKL-40 plasma levels and BMI.…”

Section: Discussionsupporting

confidence: 51%

Evaluation of YKL-40 Serum Level in Patients with Type 1 Diabetes and Its Correlation with Their Metabolic and Renal Conditions

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 51%

Evaluation of YKL-40 Serum Level in Patients with Type 1 Diabetes and Its Correlation with Their Metabolic and Renal Conditions

et al. 2017

View full text Add to dashboard Cite

show abstract

“…14,18,19 Recently, several clinical studies have described an association between increased YKL-40 levels, and several cardiovascular conditions, myocardial infarction, atrial fibrillation, and mortality. 10,20,21 PEX is a disorder of the extracellular matrix that is frequently related to severe chronic secondary open-angle glaucoma. 2 Extraocular deposition of pseudoexfoliation material has been localized to the connective tissues or septa traversing the organ tissue.…”

Section: Resultsmentioning

confidence: 99%

“…8 Increased serum YKL-40 concentration has been found to be associated with cardiovascular morbidity. 9,10 It has been also displayed that YKL-40 could be used as a biomarker for atherosclerosis at very early stages of cardiovascular diseases. 11 We hypothesized that YKL-40 could have a role in the pathogenesis of PEX.…”

Section: Introductionmentioning

confidence: 99%

Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome

Türkyılmaz

Oner

Kırbaş

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To evaluate serum levels of YKL-40 in patients with pseudoexfoliation syndrome (PEX) in comparison with those of age-and sex-matched healthy subjects. Methods Forty patients with PEX (PEX group) and 40 age-and sex-matched control subjects (control group) were enrolled in the study. An enzyme immunoassay method using the commercially available test MicroVue YKL-40 was used to measure serum YKL-40 concentration. Systolic and diastolic blood pressures, serum levels of high sensitivity C-reactive protein (hsCRP), total cholesterol, low-density lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol (HDL), and triglycerides were also examined. Results The mean age was 54.4 ± 7.6 (ranging 41-65) years in each group. The mean serum YKL-40 level of the PEX group was significantly higher than that of the control group (Po0.001). In addition, the mean serum HsCRP, total cholesterol, LDL, and triglycerides levels were significantly higher, and mean serum HDL level was significantly lower in the PEX group than in the control group (all Po0.001, excluding both P ¼ 0.002 for triglycerides and HDL levels). Further, the mean systolic and diastolic blood pressures were significantly higher in the PEX group than in the control group (P 1 ¼ 0.001 and P 2 ¼ 0.01, respectively). Conclusion We have shown a relationship between PEX and elevated serum levels of YKL-40. We imply that a better understanding of the role of YKL-40 in the pathogenesis of endothelial dysfunction and atherosclerosis is necessary to develop new therapies for preventing or treating PEX. Further studies are warranted to clarify the clinical relevance of these findings.

show abstract

“…9 This hypothesis was recently verified in clinical settings in patients with coronary artery disease. 15 Two recent studies demonstrated significantly elevated levels of YKL-40 in patients with type II diabetes as well as a positive correlation with insulin resistance and lipid disturbances. 8,9 This study was carried out to test the possibility that antihypertensive treatment with moxonidine may induce more favorable effects than the dihydropyridine calcium antagonist amlodipine on insulin resistance, serum lipids, uric acid and a new cardiovascular risk marker, YKL-40.…”

Section: Introductionmentioning

confidence: 99%

Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients—a randomized, crossover trial

2010

View full text Add to dashboard Cite

Moxonidine is a selective imidazoline receptor agonist with comparable blood pressure-lowering efficacy to first-line antihypertensives and favorable metabolic effects. YKL-40 (chitinase-3-1-protein) has been proposed as a new marker of inflammation, atherosclerosis and endothelial dysfunction in neoplastic, cardiovascular and metabolic diseases but has not yet been studied in the context of essential hypertension. Fifteen patients (10 M, 5 F; age 48 ± 14 years) with arterial hypertension and insulin resistance (HOMA-IR index 42.77) on at least two antihypertensive drugs were randomized to receive either moxonidine (0.4 mg) or amlodipine (10 mg) for two 8-week periods with a 7-day wash-out. Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase. Mean BP decreased significantly with both moxonidine and amlodipine (À9.8 ± 7.6 and À10.4 ± 7.3 mm Hg, respectively). Serum high-density lipoprotein cholesterol increased with both therapies, but only moxonidine-affected serum triglycerides. No significant changes in serum uric acid, CRP, YKL-40 (2.3 and 3.3 ng ml -1 , respectively) or HOMA index (0.70 ± 2.4 and 0.76 ± 2.8) were observed. There was a strong negative correlation between serum uric acid and YKL-40 concentration at baseline (r¼À0.77, P¼0.01). Serum YKL-40 did not correlate with blood pressure, biochemical parameters or HOMA index. Moxonidine is an effective adjunctive antihypertensive agent for use in patients with hypertension and insulin resistance that induces beneficial effects on serum lipid profile but does not reduce insulin resistance, inflammation or serum YKL-40 concentration.

show abstract

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

Abstract: High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.

Cited by 156 publications

References 31 publications

Evaluation of YKL-40 Serum Level in Patients with Type 1 Diabetes and Its Correlation with Their Metabolic and Renal Conditions

Evaluation of YKL-40 Serum Level in Patients with Type 1 Diabetes and Its Correlation with Their Metabolic and Renal Conditions

Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome

Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients—a randomized, crossover trial

Contact Info

Product

Resources

About